Russia confirms deal with Dr. Reddy's for COVID-19 vaccine 'Sputnik V' trials in India, to supply 100 million doses
Wednesday, 16 September 2020 () Russia's sovereign wealth fund on Wednesday agreed to supply 100 million doses of world's first COVID-19 vaccine Sputnik-V to Indian drug company Dr Reddy's Laboratories as Moscow speeds up plans to distribute its shot abroad.
As clinical trials of different COVID-19 vaccines are in various phases across the globe, an AIIMS (All India Institute of Medical Sciences) doctor said that if everything goes as planned, people can expect a vaccine as early as the starting of next year. "Phase 2 clinical trial for COVID-19 vaccine...
Hyderabad-based pharma company Bharat Biotech to conduct phase 3 clinical trial tests in October. Uttar Pradesh Health Minister Jai Pratap Singh said around 3,000 people to be tested under the phase 3 trial of the vaccine candidate. Bharat Biotech is working with the Indian Council of Medical Research (ICMR) to develop a vaccine candidate – Covaxin. The pharma company recently signed an agreement with the Washington University School of Medicine for an intranasal single-dose vaccine. Watch the full video for more details.
Credit: HT Digital Content Duration: 02:29Published
A one-man climate movement is looking to build momentum to force the Russian government to take action. Arshak Makichyan has been standing alone on the streets of Moscow to raise awareness and gather support for his cause. Adam Reed reports.
Kremlin critic Alexei Navalny has been discharged from the hospital in Berlin where he has been treated after falling ill on a domestic flight in Siberia last month. The German government says he was poisoned with the nerve agent, Novichok. Emer McCarthy reports.
India and China have been engaged in a tussle at the LAC in Ladakh since May 2020. After the tussle turned violent in Galwan valley, leading to casualties on both sides, talks have been underway but no headway has been made. The Defence and Foreign Ministers of the two countries have also met in Moscow to discuss the border situation. The Chinese Army has made several aggressive moves, attempting to change the status quo unilaterally in the past few months. Each time Indian forces have responded in equal measure to push back the Chinese. Indian Special Forces also managed to capture key strategic heights on the Southern banks of Pangong Tso in late August, giving Indian forces a key advantage. So what are the options on the table for India to tackle China’s nefarious designs at the LAC? Lt General DS Hooda(Retd) tells Hindustan Times’ Aditi Prasad that India has the option of using special forces across the border. He added that if the situation arises, India has the ability to carry out cross-LAC operations. Watch the full video for all the details.
Credit: HT Digital Content Duration: 06:06Published
Equity benchmark indices were down on September 30. At 10:00 am, the BSE was down by 95 points or 0.25 per cent and was trading at 37,876, while Nifty was trading also dipped by 7 points or -0.06 per cent at 11,215. The top gainers in the BSE include Sun Pharma, HUL and Asian Paints. SunPharma was trading up with shares at Rs 512 points up by 1.57 per cent, HUL was at Rs 2,055 and Asian Paints at Rs 1,979. Top gainers at NSE included CIPLA, Dr Reddy and Divi's Laboratories Limited. CIPLA was trading at Rs 789 up by 3.49 per cent, Dr Reddy at Rs 5,225 up by 2.77 per cent and Divi's Laboratories Limited was trading at Rs 3,119.
Equity benchmark indices traded higher during early hours on Friday amid mixed cues from their Asian peers. At 10:15 am, the BSE S-P Sensex was up by 136 points or 0.35 per cent at 39,115 while the Nifty 50 moved up by 56 points or 0.48 per cent at 11,576. Except for Nifty FMCG, all sectoral indices at the National Stock Exchange were in the green with Nifty pharma gaining by 3.8 per cent, realty by 0.9 per cent and auto by 0.7 per cent. Among stocks, Dr Reddy's Laboratories jumped by 4.6 per cent to Rs 5,051.20 per share after the company said it has settled its patent litigation with Celgene for the latter's cancer drug capsules. Cipla ticked up by 5.4 per cent and Sun Pharma by 3 per cent while Oberoi Realty advanced by 2.4 per cent. Eicher Motors, Adani Ports, Tech Mahindra and Wirpo traded with a positive bias. FMCG stocks fell with Hindustan Uniliver slipping by 1.4 per cent, Nestle India by 0.3 per cent and Britannia by 0.2 per cent.
Equity benchmark indices traded higher in the afternoon session on September 16 while Asian stocks were flat ahead of the US Federal Reserve's view on the economy. The BSE S-P Sensex closed 259 points or 0.66 per cent at 39,303 while the Nifty 50 gained by 83 points or 0.72 per cent at 11,605. Except for Nifty media and PSU bank, all sectoral indices at the National Stock Exchange were in the positive zone with Nifty realty gaining by 2.2 per cent, pharma by 2 per cent and auto by 1.5 per cent. Among stocks, Dr Reddy's jumped by 4.44 per cent to close at Rs 4,639.60 per share after it announced cooperation with Russian Direct Investment Fund (RDIF) to conduct clinical trials and distribute Sputnik V vaccine in India for treatment of COVID-19. Mahindra - Mahindra accelerated by 4 per cent to Rs 638.05 per share while Bajaj Auto moved up by 3.5 per cent and Tata Motors by 1.7 per cent.
India has received an offer from Russia to conduct a trial and manufacture its "Sputnik-V" COVID-19 vaccine, with several Indian companies currently studying the proposal, an Indian government official said on Tuesday. "The government of India attaches great importance to this offer of partnership from a friend," said V. K. Paul, member of NITI Aayog.
Credit: HT Digital Content Duration: 03:32Published
Russia's sovereign wealth fund on Wednesday agreed to supply 100 million doses of world's first COVID-19 vaccine Sputnik-V to Indian drug company Dr Reddy's... DNA Also reported by •IndiaTimes •Mid-Day •Indian Express